526 related articles for article (PubMed ID: 32439653)
1. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
2. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
[TBL] [Abstract][Full Text] [Related]
3. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
4. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A; Tykodi SS; Daniels GA; Maio M; Curti BD; Lewis KD; Jang S; Kalinka E; Puzanov I; Spira AI; Cho DC; Guan S; Puente E; Nguyen T; Hoch U; Currie SL; Lin W; Tagliaferri MA; Zalevsky J; Sznol M; Hurwitz ME
J Clin Oncol; 2021 Sep; 39(26):2914-2925. PubMed ID: 34255535
[TBL] [Abstract][Full Text] [Related]
5. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Huddart RA; Siefker-Radtke AO; Balar AV; Bilen MA; Powles T; Bamias A; Castellano D; Khalil MF; Van Der Heijden MS; Koshkin VS; Pook DW; Özgüroğlu M; Santiago L; Zhong B; Chien D; Lin W; Tagliaferri MA; Loriot Y
Future Oncol; 2021 Jan; 17(2):137-149. PubMed ID: 32938232
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
7. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract][Full Text] [Related]
8. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
9. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
[TBL] [Abstract][Full Text] [Related]
10. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Tannir NM; Papadopoulos KP; Wong DJ; Aljumaily R; Hung A; Afable M; Kim JS; Ferry D; Drakaki A; Bendell J; Naing A
Int J Cancer; 2021 Jul; 149(2):403-408. PubMed ID: 33709428
[TBL] [Abstract][Full Text] [Related]
11. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Khushalani NI; Diab A; Ascierto PA; Larkin J; Sandhu S; Sznol M; Koon HB; Jarkowski A; Zhou M; Statkevich P; Geese WJ; Long GV
Future Oncol; 2020 Oct; 16(28):2165-2175. PubMed ID: 32723187
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
14. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Siefker-Radtke AO; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Hurwitz ME; Tannir NM
Eur Urol; 2022 Oct; 82(4):365-373. PubMed ID: 35643589
[TBL] [Abstract][Full Text] [Related]
15. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Tannir NM; Cho DC; Diab A; Sznol M; Bilen MA; Balar AV; Grignani G; Puente E; Tang L; Chien D; Hoch U; Choudhury A; Yu D; Currie SL; Tagliaferri MA; Zalevsky J; Siefker-Radtke AO; Hurwitz ME
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444058
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
17. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
18. A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Bentebibel SE; Hurwitz ME; Bernatchez C; Haymaker C; Hudgens CW; Kluger HM; Tetzlaff MT; Tagliaferri MA; Zalevsky J; Hoch U; Fanton C; Aung S; Hwu P; Curti BD; Tannir NM; Sznol M; Diab A
Cancer Discov; 2019 Jun; 9(6):711-721. PubMed ID: 30988166
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
20. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]